

AMENDMENTS TO THE CLAIMSListing of the Claims

Claims 1-52 (canceled).

53. (currently amended) A method of inhibiting mutagenesis in an organism, which method comprises administering to the organism, an effective anti-mutagenic amount of an extract from *Aristolochia taliscana*, said extract having been prepared by a process which includes extracting plant material from *Aristolochia taliscana* with an organic solvent.

Claims 54-56 (canceled).

57. (previously presented) A method of inhibiting fungal growth in a substrate, which method comprises administering to the substrate an effective anti-fungal amount of an extract from *Aristolochia taliscana*, said extract having been prepared by a process which includes extracting plant material from *Aristolochia taliscana* with an organic solvent.

Claim 58 (canceled).

59. (previously presented) A method according to Claim 53 wherein the extract contains at least 10% by weight of a eupomatenoid.

60. (previously presented) A method according to Claim 59 wherein the extract contains eupomatenoid-7.

Claims 61-62 (canceled).

63. (previously presented) A method according to Claim 57 wherein the extract contains at least 10% by weight of a eupomatenoid.

64. (previously presented) A method according to Claim 63 wherein the extract contains eupomatenoid-7.

65. (currently amended) A composition comprising an extract from *Aristolochia taliscana*, wherein the extract has been prepared by  
drying plant material from *Aristolochia taliscana*,  
pulverizing the plant material,  
suspending the plant material in organic solvent to produce a suspension,  
extracting the suspension ~~at room temperature~~ to generate an extract,  
wherein the extract contains at least 10% by weight of a eupomatenoid.

66. (previously presented) A composition according to Claim 65 wherein the extract contains at least 20% of a eupomatenoid.

67. (previously presented) A composition according to Claim 65 wherein the extract contains at least 25% of a eupomatenoid.

68. (previously presented) A pharmaceutical composition comprising a pharmaceutically acceptable carrier and an extract from *Aristolochia taliscana* wherein the extract has been prepared by extraction of plant material from the Aristolochia species with an organic solvent, wherein the extract contains at least 25% by weight of a phenolic eupomatenoid compound, at least 8% of Licarin-A and at least 8% by weight of a non-phenolic eupomatenoid compound.

69. (previously presented) A composition according to Claim 68 wherein the phenolic eupomatenoid compound is eupomatenoid-7.

71. (previously presented) A composition according to Claim 68 wherein the phenolic eupomatenoid compound is eupomatenoid-8.

Claim 71 (canceled)

72. (previously presented) A method according to Claim 59 wherein the extract contains eupomatenoid-1.

73. (previously presented) A method according to Claim 59 wherein the extract contains licarin-A.

Claims 74-80 (withdrawn).